Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

210
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
210
GPCRs Regulate Adenylyl Cylase Activity01:09

GPCRs Regulate Adenylyl Cylase Activity

5.8K
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
5.8K
Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

324
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
324
Transducer Mechanism: G Protein–Coupled Receptors01:30

Transducer Mechanism: G Protein–Coupled Receptors

2.2K
G Protein–Coupled Receptors (GPCRs) are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to various stimuli. GPCRs regulate critical physiological pathways and are excellent drug targets for treating diseases such as diabetes, cancer, obesity, depression, or Alzheimer's. Nearly 35% of approved drugs implement their therapeutic effects by selectively interacting with specific GPCRs.
GPCRs are also called heptahelical,...
2.2K
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

283
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
283

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A descriptive case series of hepatotoxicity associated with CFTR modulators and possible relevance of pharmacogenetic polymorphisms in cystic fibrosis patients.

British journal of clinical pharmacology·2026
Same author

Distal Airway Inflammation Is Linked to Small Airway Dysfunction in Asthma.

Medical sciences (Basel, Switzerland)·2026
Same author

Clinical characteristics and outcomes in the adult cystic fibrosis population in Europe from 2014 to 2024: analysis of the European Cystic Fibrosis Society Patient Registry.

The Lancet. Respiratory medicine·2026
Same author

Guidance for chest-CT in children and adults with cystic fibrosis: A European perspective (part 2: special situations/respiratory complications).

Respiratory medicine·2026
Same author

Pregnancy-related effect on elexacaftor, tezacaftor and ivacaftor pharmacokinetics in women with cystic fibrosis.

British journal of clinical pharmacology·2026
Same author

Physiologically Based Pharmacokinetic Modeling of Elexacaftor/Tezacaftor/Ivacaftor in Infants With Cystic Fibrosis.

CPT: pharmacometrics & systems pharmacology·2026
Same journal

Monographic Issue on New Concepts in Acute Exacerbations of COPD.

Seminars in respiratory and critical care medicine·2026
Same journal

Bidirectional Clinical Interactions among Exacerbations and Comorbidities in COPD: A Narrative Review.

Seminars in respiratory and critical care medicine·2026
Same journal

Radiological Approach to Severe Respiratory Infections and Pulmonary Complications in Immunocompromised Patients.

Seminars in respiratory and critical care medicine·2026
Same journal

Two Sides of the Same Smoke: Decoding Respiratory Bronchiolitis-Associated Interstitial Lung Disease and Alveolar Macrophage Pneumonia.

Seminars in respiratory and critical care medicine·2026
Same journal

Role of Vaccination in the Prevention of ECOPD.

Seminars in respiratory and critical care medicine·2026
Same journal

Acute Exacerbation of Chronic Obstructive Pulmonary Disease: Pharmacological Treatment of AECOPD New Perspectives.

Seminars in respiratory and critical care medicine·2026
See all related articles

Related Experiment Video

Updated: Aug 16, 2025

Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients
07:04

Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients

Published on: February 11, 2017

19.4K

CFTR Modulators: Current Status and Evolving Knowledge.

Lucile Regard1,2,3, Clémence Martin1,2,3, Jennifer Da Silva1,3

  • 1Department of Respiratory Medicine and French Cystic Fibrosis National Reference Center, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Paris, France.

Seminars in Respiratory and Critical Care Medicine
|December 19, 2022
PubMed
Summary
This summary is machine-generated.

The development of CFTR modulators has transformed cystic fibrosis care, improving lung function and reducing exacerbations. Early use of these highly effective modulator therapies (HEMTs) in younger patients may offer even greater benefits.

More Related Videos

Functional Reconstitution and Channel Activity Measurements of Purified Wildtype and Mutant CFTR Protein
09:59

Functional Reconstitution and Channel Activity Measurements of Purified Wildtype and Mutant CFTR Protein

Published on: March 9, 2015

12.3K
A Fluorescence-Based Assay of Membrane Potential for High-Throughput Functional Study of Two Endogenous Ion Channels in Two Epithelial Cell Lines
06:59

A Fluorescence-Based Assay of Membrane Potential for High-Throughput Functional Study of Two Endogenous Ion Channels in Two Epithelial Cell Lines

Published on: June 22, 2022

2.2K

Related Experiment Videos

Last Updated: Aug 16, 2025

Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients
07:04

Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients

Published on: February 11, 2017

19.4K
Functional Reconstitution and Channel Activity Measurements of Purified Wildtype and Mutant CFTR Protein
09:59

Functional Reconstitution and Channel Activity Measurements of Purified Wildtype and Mutant CFTR Protein

Published on: March 9, 2015

12.3K
A Fluorescence-Based Assay of Membrane Potential for High-Throughput Functional Study of Two Endogenous Ion Channels in Two Epithelial Cell Lines
06:59

A Fluorescence-Based Assay of Membrane Potential for High-Throughput Functional Study of Two Endogenous Ion Channels in Two Epithelial Cell Lines

Published on: June 22, 2022

2.2K

Area of Science:

  • Pulmonary Medicine
  • Genetics
  • Pharmacology

Background:

  • Cystic fibrosis (CF) is caused by mutations in the CF transmembrane conductance regulator (CFTR) gene.
  • Early CFTR modulators like ivacaftor (IVA) were effective for specific mutations but limited for others.
  • The development of correctors and combination therapies has expanded treatment options.

Purpose of the Study:

  • To review the advancements in CFTR modulator therapies over the past decade.
  • To discuss the efficacy of highly effective modulator therapies (HEMTs) on CF manifestations.
  • To explore the impact of early HEMT initiation in pediatric CF patients.

Main Methods:

  • Review of clinical trials and real-world studies on CFTR modulators.
  • Analysis of HEMT efficacy on respiratory and extrapulmonary manifestations.
  • Examination of HEMT impact on CF patient demographics and early-life interventions.

Main Results:

  • CFTR modulators, including IVA and triple combination therapies (e.g., elexacaftor/tezacaftor/ivacaftor), have significantly improved respiratory outcomes.
  • HEMTs are approved for approximately 90% of CF patients over six years old.
  • Evidence suggests earlier HEMT use in children and infants may enhance benefits.

Conclusions:

  • CFTR modulators represent a major breakthrough in CF management.
  • HEMTs have revolutionized care, improving quality of life and clinical outcomes.
  • Further research into early-life HEMT interventions is warranted to maximize long-term benefits.